Crenolanib besylate

CAS No.	670220-93-6	Cat. No.	BCP24113
Name	Crenolanib besylate
Synonyms	Crenolanib besilate; CP 868596; CP868596; CP-868596; ARO 002; RO-002; RO002;
Formula	C32H35N5O5S	M. Wt	601.72

Description	Crenolanib Besylate is the besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.
Pathways	Angiogenesis/Protein Tyrosine Kinase
Targets	PDGFR

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.